Promis Neurosciences (PMN) Stock Price, News & Analysis

Company Overview

Promis Neurosciences, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation. The company’s pipeline reflects a commitment to addressing unmet needs in neurology by optimizing compound profiles for safety, selectivity and central nervous system penetration.

Promis Neurosciences collaborates with academic institutions and industry partners to accelerate its research and development efforts. These strategic alliances support biomarker identification, translational studies and clinical trial design, aiming to streamline candidate advancement and enrich patient selection strategies.

The company is headquartered in the United States and its common stock trades on the Nasdaq stock exchange under the symbol PMN.

Key Stats

• Today's Range: $10.88 to $11.49
• 50-Day Range: $10.70 to $24.79
• 52-Week Range: $6.27 to $39.75
• Volume: 11,460 shs
• Average Volume: 135,418 shs
• Market Capitalization: $99.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.67
• Consensus Rating: Moderate Buy

Promis Neurosciences Stock Analysis - MarketRank™

Promis Neurosciences scored higher than 58% of companies evaluated by MarketBeat, and ranked 377th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Promis Neurosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Promis Neurosciences has a consensus price target of $42.67, representing about 285.8% upside from its current price of $11.06.

Amount of Analyst Coverage

Promis Neurosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Promis Neurosciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Promis Neurosciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.67% of the float of Promis Neurosciences has been sold short.

Short Interest Ratio / Days to Cover

Promis Neurosciences has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Promis Neurosciences has recently decreased by 19.88%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Promis Neurosciences does not currently pay a dividend.

Dividend Growth

Promis Neurosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Promis Neurosciences this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for PMN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Promis Neurosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of Promis Neurosciences in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $140,855.00 in company stock, which represents 0.1420% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Promis Neurosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $140,855.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

1.50% of the stock of Promis Neurosciences is held by insiders.

Percentage Held by Institutions

50.13% of the stock of Promis Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PMN Stock Analysis - Frequently Asked Questions

How have PMN shares performed this year?

Promis Neurosciences' stock was trading at $6.8250 at the start of the year. Since then, PMN shares have increased by 62.1% and is now trading at $11.06.

How were Promis Neurosciences' earnings last quarter?

Promis Neurosciences (NASDAQ:PMN) released its quarterly earnings data on Wednesday, November, 12th. The company reported ($6.00) earnings per share for the quarter, missing the consensus estimate of ($3.75) by $2.25.

When did Promis Neurosciences' stock split?

Promis Neurosciences's stock reverse split on the morning of Friday, November 28th 2025.A 1-25 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Promis Neurosciences?

Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Promis Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Promis Neurosciences investors own include PayPal (PYPL), Recursion Pharmaceuticals (RXRX), Pacific Biosciences of California (PACB), Editas Medicine (EDIT), Trimble (TRMB).

Company Calendar

• Last Earnings: 11/12/2025
• Today: 5/06/2026
• Next Earnings (Estimated): 5/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PMN
• CIK: 1374339
• Web: www.promisneurosciences.com
• Phone: (416) 847-6898
• Fax: N/A
• Employees: 5
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Promis Neurosciences: $42.67
• High Price Target: $75.00
• Low Price Target: $18.00
• Potential Upside/Downside: +285.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($19.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.72 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -933.63%
• Return on Assets: -295.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.88
• Quick Ratio: 0.88

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.58) per share
• Price / Book: -19.08

Miscellaneous

• Outstanding Shares: 8,970,000
• Free Float: 8,833,000
• Market Cap: $99.25 million
• Optionable: Not Optionable
• Beta: -0.20